NVS·NYSE·US
Novartis
Novartis is a global pharmaceutical company focused on innovative medicines across oncology, immunology, neuroscience, cardiovascular, renal, and metabolic disease areas. It also has meaningful exposure to advanced therapies, including cell and gene therapy, as part of its biopharmaceutical portfolio.
Recent Activity
Updated Oct 31, 2026
–Novartis reported Q3 net sales growth of 4% in constant currencies and core operating income growth of 10% in constant currencies, and raised its full-year core operating income guidance.
–The European Commission approved Novartis' Cosentyx (secukinumab) for adults with polymyalgia rheumatica, making it the first and only IL-17A inhibitor approved in Europe for the condition.
–Novartis wrote off part of its Avidity deal.
–Novartis CEO Vas Narasimhan said remibrutinib could be one of the company's largest medicines in history.
–Novartis announced fatal events in an autoimmune cell therapy trial.
–Novartis has had a series of clinical trial setbacks, including disappointing data, that challenge its effort to build its next generation of blockbuster medicines.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.
Recent Discoveries
Recent discoveries are part of the Pro plan.